NASDAQ:ARQT Arcutis Biotherapeutics Q3 2026 Earnings Report $25.16 -0.13 (-0.51%) Closing price 04:00 PM EasternExtended Trading$25.16 0.00 (-0.02%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Arcutis Biotherapeutics EPS ResultsActual EPSN/AConsensus EPS $0.19Beat/MissN/AOne Year Ago EPSN/AArcutis Biotherapeutics Revenue ResultsActual RevenueN/AExpected Revenue$141.69 millionBeat/MissN/AYoY Revenue GrowthN/AArcutis Biotherapeutics Announcement DetailsQuarterQ3 2026Date10/27/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Arcutis Biotherapeutics Earnings HeadlinesArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2 at 4:00 PM | globenewswire.comArcutis Partners With Simone Biles To Raise Awareness Of Skin ConditionsSeptember 29 at 2:51 PM | rttnews.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.October 2 at 1:00 AM | InvestorPlace (Ad)Arcutis Biotherapeutics Inc (ARQT)September 24, 2026 | in.investing.comHere’s What Arcutis’ CEO Said at the Morgan Stanley Healthcare Conference That Made the Stock Jump 11%September 18, 2026 | finance.yahoo.comArcutis Biotherapeutics, Inc. (ARQT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comSee More Arcutis Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Arcutis Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arcutis Biotherapeutics and other key companies, straight to your email. Email Address About Arcutis BiotherapeuticsArcutis Biotherapeutics (NASDAQ:ARQT) (NASDAQ: ARQT) is a biopharmaceutical company focused on developing and commercializing treatments for dermatologic conditions. The company concentrates on medical dermatology, with an emphasis on addressing diseases that can significantly affect patients’ quality of life and for which additional treatment options are needed. Arcutis’s primary commercial product is ZORYVE (roflumilast), a topical phosphodiesterase-4 inhibitor available in multiple formulations. ZORYVE has been approved in the United States for certain indications including plaque psoriasis, seborrheic dermatitis and atopic dermatitis, depending on the formulation and patient population. The company continues to evaluate and expand the product’s potential uses in inflammatory skin diseases. Founded in 2016, Arcutis is headquartered in Westlake Village, California, and serves patients and healthcare providers primarily through the U.S. dermatology market. The company is led by President and Chief Executive Officer Frank Watanabe and maintains a development strategy centered on topical and other therapies for common dermatologic conditions.View Arcutis Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes NextTarget's Holiday Blitz: Slashing Prices to Capture Market Share Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
